Pamidronate and disease activity in rheumatoid arthritis
Not Applicable
- Conditions
- Rheumatoid arthritis.Seropositive rheumatoid arthritis
- Registration Number
- IRCT138801051778N1
- Lead Sponsor
- Vice chancellery of research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Rheumatoid arthritis patients who don’t have enough clinical and laboratory response to conventional disease modifying anti rheumatic drugs (DMARDs).
Exclusion criteria: patients who don’t want to have injection or had drug allergy or hypersensitivity, Drug reaction in the course of injection or after that, Lapse from study, Immigration or death.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease activity. Timepoint: Before of injection, every month until 3 months, then 6 months after first injection. Method of measurement: DAS28.
- Secondary Outcome Measures
Name Time Method Anti inflammatory effect of pamidronate. Timepoint: Before of injection, every month until 3 months, then 6 months after first injection. Method of measurement: DAS28, ESR, VAS.